📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 18:24
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
92% Revenue Growth in Q1 FY27 Driven by Trading; Pharma Segment Reports Loss
Biofil Chemicals reported a 92% YoY revenue increase to ₹12.35 cr for Q1 FY27, primarily driven by a surge in the Chemical division's trading activities. However, Net Profit plummeted 95.4% YoY to ₹0.11 cr, largely because the base quarter (Q1 FY26) was inflated by ₹2.83 cr in Other Income. The core Pharma division reported a segment loss of ₹0.06 cr as manufacturing facilities undergo a 3-6 month renovation to comply with revised Schedule M regulations. Operating margins remain extremely thin as the company relies on trading to sustain top-line growth during this transition.
Confidence: HIGH
What changedThe company has pivoted to high-volume, low-margin chemical trading while its primary pharma manufacturing unit is offline for regulatory-driven upgrades.
Why it mattersThe sharp drop in profitability and the operational loss in the pharma segment highlight the company's current struggle to maintain margins without active manufacturing operations.
Revenue (Q1 FY27): ₹12.35 crNet Profit (Q1 FY27): ₹0.11 crRevenue vs TTM Revenue: 44.1%Pharma Segment Loss: ₹0.06 crRenovation Timeline: 3-6 months
📅 Short termThe stock may face pressure due to the significant decline in bottom-line performance and the temporary halt in core manufacturing activities.
📈 Long termLong-term recovery depends on the successful completion of facility upgrades and the company's ability to launch higher-margin products in the generics and branded segments.
⚠ Risk flags
- Operational loss in core Pharma segment
- High reliance on low-margin trading activities
- Execution risk in facility renovation timeline
- Significant drop in PAT margins
Key Highlights
Revenue from operations increased 92% YoY to ₹12.35 cr, representing ~44% of TTM revenue in a single quarter.
Net Profit fell sharply to ₹0.11 cr from ₹2.41 cr in the previous year's corresponding quarter.
Chemical division revenue grew 481% YoY to ₹9.22 cr, though it contributed only ₹0.15 cr to segment results.
Pharma division reported a segment loss of ₹6.41 lakhs compared to a profit of ₹2.70 cr in Q1 FY26.
Manufacturing facility renovation and upgradation for Schedule M compliance is expected to take 3-6 months.
👀 What to Watch
Investors should monitor the timeline for the manufacturing facility's renovation and the subsequent restart of pharma production, as current growth is low-margin trading-led.
Biofil Chemicals FY26 Net Profit Jumps 400% to ₹2.78 Cr Driven by Other Income
Biofil Chemicals reported a significant 399% increase in annual net profit to ₹278.60 lakhs for FY26, compared to ₹55.78 lakhs in FY25. This surge was primarily driven by a massive spike in 'Other Income' which reached ₹308.23 lakhs, while core revenue from operations actually declined by 15% YoY to ₹2839.52 lakhs. For the fourth quarter (Q4 FY26), the company recorded a net profit of ₹21.22 lakhs on revenue of ₹756.56 lakhs. Despite the revenue drop, the company managed to reduce its total annual expenses by 15% to ₹2802.79 lakhs.
Key Highlights
Annual net profit surged to ₹278.60 lakhs in FY26 from ₹55.78 lakhs in FY25.
Other Income spiked to ₹308.23 lakhs in FY26, up from just ₹30.52 lakhs in the previous year.
Revenue from operations for FY26 decreased by 15% to ₹2839.52 lakhs compared to ₹3340.22 lakhs in FY25.
Total annual expenses were reduced to ₹2802.79 lakhs from ₹3297.13 lakhs YoY.
Q4 FY26 revenue stood at ₹756.56 lakhs with a net profit of ₹21.22 lakhs.
👀 What to Watch
Investors should be cautious as the profit growth is largely attributed to non-operational 'Other Income' rather than core business growth. It is advisable to investigate the source of this other income and monitor if the company can reverse the declining trend in its core operational revenue.
Biofil Chemicals Q3 Revenue Plummets 94% YoY to ₹85.63 Lakhs Amid Factory Renovation
Biofil Chemicals & Pharmaceuticals reported a severe decline in its financial performance for Q3 FY26, with revenue from operations crashing to ₹85.63 Lakhs from ₹1419.52 Lakhs in the same period last year. Net profit followed suit, dropping to ₹7.92 Lakhs compared to ₹16.46 Lakhs YoY. The company attributed this massive operational disruption to mandatory factory renovations and upgrades required to comply with the revised Schedule M of the Drugs & Cosmetics Rules. Consequently, the Chemicals division reported zero revenue for the quarter, while Pharma revenue saw a drastic reduction.
Key Highlights
Revenue from operations fell by 94% YoY to ₹85.63 Lakhs from ₹1419.52 Lakhs.
Net Profit for the quarter declined 51.9% YoY to ₹7.92 Lakhs.
Chemicals division revenue dropped to zero for the quarter compared to ₹139.61 Lakhs in the preceding quarter.
Manufacturing operations were partially disrupted due to factory renovation for Schedule M compliance.
Earnings Per Share (EPS) halved to ₹0.05 from ₹0.10 in the corresponding quarter of the previous year.
👀 What to Watch
Investors should exercise caution as the company's core manufacturing is currently hampered by facility upgrades; monitor for updates regarding the completion of renovations and the timeline for resuming full-scale production.
